Literature DB >> 33512700

Bariatric Surgery and Type 2 Diabetes Remission Rates: a Retrospective Cohort Study Comparing Military Veterans and Beneficiaries.

Alexis Caponera1.   

Abstract

PURPOSE: The disease burden of type 2 diabetes (T2D) costs the military healthcare system an estimated $1.66 billion annually. Thirty-four percent of veterans and 28% of military beneficiaries are obese, a common feature of T2D. Bariatric surgery is a viable treatment for T2D, whether if long-term remission of T2D post-bariatric surgery occurs remains unknown. The purpose of this study was to assess differences between outcomes of veterans and military beneficiaries following bariatric surgery.
MATERIALS AND METHODS: A retrospective cohort study assessed retirees and beneficiaries diagnosed with T2D who had bariatric surgery between 2005 and 2015. Outcomes included T2D remission and vitamin and mineral deficiencies each year for 5 years post-op, analyzed via ANOVA.
RESULTS: Ninety-one patients, 46 beneficiaries and 45 retirees, were included with a mean age of 51 and 57, respectively. No significant differences between T2D remission and vitamin/mineral deficiencies 5 years post-op were found between groups. Patients with uncontrolled diabetes before surgery were less likely to achieve T2D remission for all 5 years post-op, regardless of military affiliation (p < .05).
CONCLUSION: Veterans do not have better rates of T2D remission or weight loss following bariatric surgery than other populations. Control of T2D pre-surgery is a potential clinical indicator of T2D remission success following bariatric surgery.

Entities:  

Keywords:  Bariatric surgery; Diabetes; Gastric sleeve; Military; Military beneficiary; Obesity; Roux-en-Y; Uncontrolled diabetes; Veteran; Vitamin deficiency

Mesh:

Year:  2021        PMID: 33512700     DOI: 10.1007/s11695-020-05169-w

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  1 in total

1.  Bariatric Surgery Provided by the Veterans Health Administration: Current State and a Look to the Future.

Authors:  William Gunnar
Journal:  J Gen Intern Med       Date:  2017-04       Impact factor: 5.128

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.